Abstract
To investigate the relationship between D2 receptors changes and disease progression, we used 123I-IBZM SPET to longitudinally assess striatal D2 receptors activity in 13 PD patients who, at baseline study, were in the early drug-naive stage of the disease (mean H-Y score: 1.7±0.6). Follow-up SPET was performed after 3.1±1.3 y (mean H-Y score: 2.1±0.7; mean daily dosage of L-Dopa: 425±136mg). Caudate EBZM uptake at the baseline study showed a significant correlation with the ensuing rate of progression of PD, measured by the H-Y annual score change (r=-0.66, p
| Original language | English |
|---|---|
| Pages (from-to) | 20 |
| Number of pages | 1 |
| Journal | Italian Journal of Neurological Sciences |
| Volume | 18 |
| Issue number | 4 |
| Publication status | Published - 1997 |
Fingerprint
ASJC Scopus subject areas
- Neuroscience(all)
- Clinical Neurology
Cite this
Striatal D2 receptors changes parallel the progression of Parkinson's disease (PD). / Pizzolato, G.; Cagnin, A.; Delibori, D.; Bracco, F.; Dam, M.; Battistin, L.; Chierichetti, F.; Ferlin, G.
In: Italian Journal of Neurological Sciences, Vol. 18, No. 4, 1997, p. 20.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Striatal D2 receptors changes parallel the progression of Parkinson's disease (PD)
AU - Pizzolato, G.
AU - Cagnin, A.
AU - Delibori, D.
AU - Bracco, F.
AU - Dam, M.
AU - Battistin, L.
AU - Chierichetti, F.
AU - Ferlin, G.
PY - 1997
Y1 - 1997
N2 - To investigate the relationship between D2 receptors changes and disease progression, we used 123I-IBZM SPET to longitudinally assess striatal D2 receptors activity in 13 PD patients who, at baseline study, were in the early drug-naive stage of the disease (mean H-Y score: 1.7±0.6). Follow-up SPET was performed after 3.1±1.3 y (mean H-Y score: 2.1±0.7; mean daily dosage of L-Dopa: 425±136mg). Caudate EBZM uptake at the baseline study showed a significant correlation with the ensuing rate of progression of PD, measured by the H-Y annual score change (r=-0.66, p
AB - To investigate the relationship between D2 receptors changes and disease progression, we used 123I-IBZM SPET to longitudinally assess striatal D2 receptors activity in 13 PD patients who, at baseline study, were in the early drug-naive stage of the disease (mean H-Y score: 1.7±0.6). Follow-up SPET was performed after 3.1±1.3 y (mean H-Y score: 2.1±0.7; mean daily dosage of L-Dopa: 425±136mg). Caudate EBZM uptake at the baseline study showed a significant correlation with the ensuing rate of progression of PD, measured by the H-Y annual score change (r=-0.66, p
UR - http://www.scopus.com/inward/record.url?scp=33746374460&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746374460&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:33746374460
VL - 18
SP - 20
JO - Italian Journal of Neurological Sciences
JF - Italian Journal of Neurological Sciences
SN - 0392-0461
IS - 4
ER -